Recently Introduced Products

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Potential Impact</th>
<th>Expected Avg. Annual Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucynta IR</td>
<td>For the management of moderate to severe acute pain in adults</td>
<td>$</td>
<td>$2,100 - $3,100</td>
</tr>
</tbody>
</table>

$: Est. drug plan expenditure increase of <1%*  $$: Est. drug plan expenditure increase of 1-5%*  $$$: Est. drug plan expenditure increase of >5%*

**Complera® - Once daily, single tablet for the treatment of HIV**

Complera® is an antiretroviral agent that has been approved in Canada for treatment of HIV-1 infection in adults who have not received previous therapy.¹ It is a fixed-dose triple combination tablet. This combination represents a new complete Highly Active AntiRetroviral Therapy (HAART) regimen formulated in a single tablet that is dosed once daily.¹

At the end of 2008, there were an estimated 65,000 people in Canada living with HIV (including AIDS) - 26% were unaware of their infection.² The number of newly infected people was estimated to be between 2,300 and 4,300.² Over the past 20 years, the HIV population is living longer due to the successful intervention of HAART.

There is currently no cure for HIV. The goals of therapy are to prolong survival, slow disease progression and reduce HIV related morbidity. However, due to the pill burden associated with HIV treatment, these goals are challenged as a result of noncompliance. Current HIV treatment guidelines recommend a specific three-drug combination. Complera® offers this complete combination in a single tablet. It allows for reduced dosing frequency and pill burden which results in increased patient acceptance and adherence to HAART.

Complera® offers a new treatment option for both physicians and patients as it combines the benefits of a single tablet regimen with a favourable tolerability profile. Complera® costs approximately $13,500 per year, priced in line with Atripla, the only other once daily, fixed dose combination single tablet. The annual cost of Complera® represents an approximate 6% savings compared to the separate components.

Since Complera® has demonstrated efficacy and a unique tolerability profile in a single tablet regimen along with a cost that is comparable to other first line therapies, Complera® will be fully covered under both open formularies and for clients who subscribe to ClaimSecure’s Managed Formularies and Specialty Drug Programs. Many ClaimSecure clients place all HIV medications under special authorization as determined by contractual agreements. For clients who choose this option, Complera® will be placed under special authorization, where the priority will be to coordinate coverage with the provincial drug programs.

*If you require additional information about Complera®, please contact Lavina Viegas, Clinical Pharmacist, Clinical Services Department, at (905) 949-3031 or 1-888-479-7587 ext. 3031.*

**Recommendation: Full Coverage**

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References:

* Based on the Financial Impact Analysis per 100,000 lives covered © 2012 ClaimSecure Inc.